AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$KOD

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of KOD (indirect holdings)

BAKER BROS. ADVISORS LP purchased 418,323 indirectly-held shares of Kodiak Sciences Inc. (KOD) at an average of $83.58 ($79.40–$85.97, $34.96M total) across 30 trades on 2026-09-28. Filed jointly with 667, L.P. (Director), Baker Bros. Advisors (GP) LLC (Director), Baker Brothers Life Sciences LP (Director), BAKER FELIX (Director) and BAKER JULIAN (Director).

Original reporting
SEC EDGAR · BAKER BROS. ADVISORS LP, 667, L.P., Baker Bros. Advisors (GP) LLC, Baker Brothers Life Sciences LP, BAKER FELIX, BAKER JULIAN
Published Sep 30, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KOD
Bullish
high confidence
Mentioned
$KOD
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KODBullishMed
01

Why it matters

The filing provides fresh, material information about insider confidence, which can influence short‑term price dynamics.

02

Market read

Primary insider purchase likely to generate buying interest in KOD and affect related biotech sentiment.

03

What to watch

The purchase was made via an indirect holding; actual control may be less direct than it appears.

Relevance 8/10Novelty 7/10Timing: post‑market 2026‑09‑30

Background

SEC Form 4 filed by Baker Bros. Advisors LP discloses a large open‑market purchase of Kodiak Sciences shares.

Company-level read

Ticker impact

$KODBullishHigh confidence
Context

Director and 10% owner purchased 418,323 shares for $35M, increasing holdings to 19.5M shares.

Expected impact

likely upward pressure as market prices in the insider buy

Evidence & confidence

The $35M purchase represents a material increase for a small‑cap biotech and is disclosed as a primary Form 4 filing.

Market effects

Sector

May signal confidence in Kodiak's pipeline, potentially boosting other small‑cap biotech sentiment.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to niche biotech space.

Counterpoint

What could challenge this read

Insider buying could be a defensive move ahead of upcoming clinical trial risk.

Key entities

  • company
    Kodiak Sciences Inc.

    Biotech firm developing therapies for liver diseases.

  • insider
    Baker Bros. Advisors LP

    Director and 10% owner executing the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KOD insider trading history →

Related articles

OCT 2
$KODHighAI 9/10

Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study

Kodiak Sciences reported positive Phase III study results for its wet AMD treatments, Zenkuda and tabirafusp-ted, showing non-inferiority to aflibercept. Zenkuda met primary endpoints, with 54% of patients reaching a 24-week dosing interval. Tabirafusp-ted demonstrated equivalence in visual acuity. The company plans to submit a multi-indication biologics license application for Zenkuda this year and continues Phase III trials for tabirafusp-ted in DME and KSI-101 in macular edema.

finance.yahoo.com2 min
OCT 2
$KODMed

Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.

rttnews.com2 min
SEP 30
High

Kodiak Sciences: Baker Bros. reports 35% stake

Baker Bros. Advisors LP and related entities reported a 35% stake in Kodiak Sciences Inc., acquiring additional common stock. Felix J. Baker, a managing member, serves on the board and holds vested stock options. The investment is for long-term purposes, with potential for further purchases or disposals based on market conditions and company prospects.

stocktitan.net2 min
SEP 30
$KODMedAI 9/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $63.4M of KOD (indirect holdings)

BAKER BROS. ADVISORS LP purchased 715,592 indirectly-held shares of Kodiak Sciences Inc. (KOD) at an average of $88.59 ($84.24–$89.86, $63.40M total) across 22 trades over 2026-09-28 to 2026-09-29. Filed jointly with 667, L.P. (Director), Baker Bros. Advisors (GP) LLC (Director), Baker Brothers Life Sciences LP (Director), BAKER FELIX (Director) and BAKER JULIAN (Director).

SEC EDGAR1 min
SEP 30
$KODMedAI 8/10

Kodiak Sciences: Baker funds buy 808K shares

Kodiak Sciences (KOD) shares were purchased by Baker funds, totaling 807,840 shares on September 28, 2026, at prices ranging from $61.21 to $78.57 per share. The purchases were made by 667, L.P. and Baker Brothers Life Sciences, L.P., with no Rule 10b5-1 plan reported. The total value of the transactions exceeded $50 million.

stocktitan.net2 min